Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 382

The DOI matches its Crossref record; 300 of the 300 references it cites were found in a registry or an index.

MMP‐9 in translation: from molecule to brain physiology, pathology, and therapy

Open access
Vafadari, Behnam, Salamian, Ahmad, Kaczmarek, Leszek·2016·Journal of Neurochemistry

Abstract

Matrix metalloproteinase‐9 (MMP‐9) is a member of the metzincin family of mostly extracellularly operating proteases. Despite the fact that all of these enzymes might be target promiscuous, with largely overlapping catalogs of potential substrates,MMP‐9 has recently emerged as a major and apparently unique player in brain physiology and pathology. The specificity of MMP‐9 may arise from its very local and time‐restricted actions, even when released in the brain from cells of various types, including neurons, glia, and leukocytes. In fact, the quantity of MMP‐9 is very low in the naive brain, but it is markedly activated at the levels of enzymatic activity, protein abundance, and gene expression following various physiological stimuli and pathological insults. Neuronal MMP‐9 participates in synaptic plasticity by controlling the shape of dendritic spines and function of excitatory synapses, thus playing a pivotal role in learning, memory, and cortical plasticity. When improperly unleashed,MMP‐9 contributes to a large variety of brain disorders, including epilepsy, schizophrenia, autism spectrum disorder, brain injury, stroke, neurodegeneration, pain, brain tumors, etc. The foremost mechanism of action of MMP‐9 in brain disorders appears to be its involvement in immune/inflammation responses that are related to the enzyme's ability to process and activate various cytokines and chemokines, as well as its contribution to blood–brain barrier disruption, facilitating the extravasation of leukocytes into brain parenchyma. However, another emerging possibility (i.e., the control of MMP‐9 over synaptic plasticity) should not be neglected. The translational potential of MMP‐9 has already been recognized in both the diagnosis and treatment domains. The most striking translational aspect may be the discovery of MMP‐9 up‐regulation in a mouse model of Fragile X syndrome, quickly followed by human studies and promising clinical trials that have sought to inhibit MMP‐9. With regard to diagnosis, suggestions have been made to use MMP‐9 alone or combined with tissue inhibitor of matrix metalloproteinase‐1 or brain‐derived neurotrophic factor as disease biomarkers. imageMMP‐9, through cleavage of specific target proteins, plays a major role in synaptic plasticity and neuroinflammation, and by those virtues contributes to brain physiology and a host of neurological and psychiatric disorders. This article is part of the60th Anniversary special issue.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/jnc.13415

Cites

300 of 300 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

3 retracted

Items 201–300 of 300

Research works printed but not linked: 12

  1. 10.3109/s10165-009-0198-5 · doi:10.3109/s10165-009-0198-5
  2. Goldenberg M. M., 2012, Multiple sclerosis review, P. T., 37, 175
  3. 10.1371/journal.pone.0028499 · doi:10.1371/journal.pone.0028499
  4. 10.1007/s00296-003-0380-6 · doi:10.1007/s00296-003-0380-6
  5. 10.2174/138920108783497631 · doi:10.2174/138920108783497631
  6. 10.1016/j.neuron.2012.10.025 · doi:10.1016/j.neuron.2012.10.025
  7. Scalea T. M., 2005, Neurotrauma: Evidence‐Based Answers To Common Questions, 3
  8. 10.1007/s12264-012-1296-5 · doi:10.1007/s12264-012-1296-5
  9. Szklarczyk A., 2005, Physiology of matrix MMPs and their tissue inhibitors in the brain, Biotech. Int., 17, 15
  10. 10.1089/neu.2009.0959 · doi:10.1089/neu.2009.0959
  11. 10.1007/s12035-014-8850-2 · doi:10.1007/s12035-014-8850-2
  12. Zhao W. J., 2012, Differential expression of MMP‐9 and AQP4 in human glioma samples, Folia Neuropathol., 50, 176

Cited by

See all 382

Metadata

Authors
Vafadari, B., Salamian, A., & Kaczmarek, L.
Venue
Journal of Neurochemistry
Publisher
Wiley
Published
2016-03-21
Volume
139
Issue
S2
Pages
91-114
ISSN
  • 0022-3042 (ISSN-L)
  • 1471-4159
OpenAlex
W1961885071
Cited by
382
References
300
FWCI
7.07
Type
journal article
Language
en
Open access
bronze
Funders
  • EXTRABRAIN 7th Framework Marie Curie European Union Initial Training Network
  • Polish Ministry of Science and Higher Education

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.